Loading company…
Molecular Intelligence X combines CRISPR and AI for gene editing, nucleic acid detection, and cell therapy research.
Founded in 2021 and based in Hangzhou, China, Molecular Intelligence X, also known as MIX, develops AI applications for gene editing and gene therapy. It combines CRISPR and artificial intelligence for nucleic acid detection research and cell drug development. MIX built a CRISPR design platform based on Zhijiang Lab's Tianshu AI platform, as well as nucleic acid detection and gene-editing immune cell platforms. Zhijiang Lab and MIX jointly established the AI Life Science Research Center, and the company holds patents related to CRISPR/Cas9.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in